Please login to the form below
Striverdi
This page shows the latest Striverdi news and features for those working in and with pharma, biotech and healthcare.
Boehringer COPD drug 'could give patients more independence'
Spiolto - which combines the active ingredients in Boehringer's long-acting muscarinic antagonist Spiriva (tiotropium) and long-acting beta agonist Striverdi (olodaterol) - was recently approved for marketing in the EU and
Latest news
-
Boehringer's Spiriva combo approved in first EU markets
s recently launched Striverdi product.
-
Boehringer bags FDA approval for Spiriva-based combo
Stiolto contains the active ingredient in Spiriva - long-acting muscarinic antagonist (LAMA) tiotropium - with long-acting beta agonist (LABA) olodaterol that is sold as a monotherapy under the Striverdi brand name.
-
FDA approves Boehringer COPD spray Striverdi Respimat
FDA approves Boehringer COPD spray Striverdi Respimat. Licence from US regulator will also allow it to treat chronic bronchitis or emphysema. ... Boehringer Ingelheim's once-daily chronic obstructive pulmonary disease (COPD) spray Striverdi Respimat
-
Boehringer submits COPD combo in EU
The drug combines Boehringer's huge selling Spiriva (tiotropium) with another of its respiratory treatments Striverdi (olodaterol). ... Striverdi is yet to hit the same lofty heights as Spiriva, having only received approval earlier this year.
-
Novartis, Boehringer stake claims to combination COPD market
up that combines tiotropium with the company's long-acting beta agonist Striverdi (olodaterol).
More from news
Approximately 2 fully matching, plus 5 partially matching documents found.
Featured jobs
-
Healthcare PR Senior Account Manager
-
Salary TBC
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
- Integrated Brand/ Digital Senior Account Director, London
-
Excellent package
-
Account Manager
-
Negotiable
- Senior Medical Writer, Principal Medical Writer, Scientific Dire...
-
£40000 - £75000 Bonus Benefits
-
Senior Medical Writer
-
Salary is DOE
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
- Senior Writer, Healthcare Advertising, London
-
Excellent package
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
-
Systematic Review Lead- London
-
Negotiable
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
-
Senior Training Manager - Surrey
-
Competitive Salary &Bonus
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
- Account Director, Healthcare Communications Agency
-
£54, 000- £60, 000
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
Subscribe to our email news alerts
- IPA’s new training course, Silver Buck launched and ARK moves office
- NHS wins legal fight with pharma over off-label Avastin
- Gilead and ViiV among winners at PM Society Digital Awards
- The critical role of science in healthcare communications
- UK pharma to work with innovation network on NHS uptake
- Bayer roll-out of haemophilia drug Jivi gathers pace
PMHub
Bedrock Healthcare Communications
Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...
Latest intelligence
- PM Society Digital Awards – the power of together
- Our chief executive, Emma Statham, writes about the value of awards and the power of together....
- Seduce anyone in four simple steps
- You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
- What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
- GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....
Quick links
Infographics
